Vevzuo and Evfraxy, denosumab biosimilars, are approved in Europe for bone health, expanding access to critical therapies with proven efficacy and safety.

• Authorized for bone cancer complications, giant cell tumors, and osteoporosis in men and postmenopausal women.
• European approval follows CHMP endorsement, marking Biocon’s expansion in biosimilars for bone disease treatments.
• Biocon aims to enhance affordable access to therapies for chronic conditions like cancer and diabetes globally.